The BTN2A1 Knockout HAP1 Polyclonal Cells product comprises a polyclonal population of HAP1 cells engineered via CRISPR/Cas9-mediated gene disruption to ablate expression of the BTN2A1 gene. This polyclonal knockout pool provides a heterogeneous mixture of edited alleles, enabling loss-of-function studies without the selection biases inherent in clonal isolation. The cells serve as a powerful tool for investigating BTN2A1-dependent phenotypes in a near-haploid genetic background.
The HAP1 host cell line is a near-haploid human cell line derived from the chronic myeloid leukemia cell line KBM-7. With an adherent, fibroblast-like morphology and a largely haploid karyotype, HAP1 cells are widely employed as a robust genetic screening model. Their simplified genome facilitates precise genome editing and reduces functional redundancy, making them particularly suited for phenotypic analyses of single-gene knockouts in signal transduction and drug target discovery.
BTN2A1 encodes a member of the butyrophilin family of immunomodulatory molecules, which functions as an inhibitory immune checkpoint. In T-cell contexts, BTN2A1 is upregulated by inflammatory signals including IFNG, TNF, and IL1B, as well as TCR activation. Mechanistically, BTN2A1 attenuates proximal T-cell receptor (TCR) signaling by inhibiting the phosphorylation of key kinases such as LCK and ZAP70, as well as the adaptor LAT, thereby suppressing downstream IL-2 and IFN-gamma production and T-cell proliferation. BTN2A1 interacts with other butyrophilin family members, the exportin XPO1, and a yet-unidentified inhibitory receptor on T cells.
In the HAP1 cellular context, BTN2A1 knockout provides an isogenic system to dissect its signaling functions independently of T-cell-specific machinery. While HAP1 cells do not naturally replicate the full TCR cascade, they can be engineered or co-cultured to reconstitute key aspects of the pathway. The near-haploid background allows unambiguous genotype-phenotype correlations and reduces confounding genetic variables, enabling precise mapping of BTN2A1 interacting networks and downstream effectors. This model is thus valuable for unbiased genetic screens aimed at identifying novel components of the BTN2A1-mediated immune regulatory axis.
Researchers can employ BTN2A1 Knockout HAP1 Polyclonal Cells in a variety of experimental workflows, including phospho-flow cytometry to assess signaling node activation, co-culture assays with T cells to measure proliferation and cytokine secretion by ELISA, and transcriptomic profiling via RNA-seq. The model supports screening for BTN2A1-interacting receptors and evaluation of candidate immunotherapies targeting the BTN2A1 checkpoint. These applications advance our understanding of T-cell inhibition mechanisms and facilitate drug discovery in autoimmune disorders, cancer, and inflammatory diseases. For further technical inquiries, please contact Ascent Research.
